期刊文献+

FLAG和MEA方案治疗难治复发性急性髓系白血病的Meta分析 被引量:9

Effectiveness of FLAG regimen and MEA regimen for refractory and relapsed acute myeloid leukemia: A Meta-analysis
下载PDF
导出
摘要 目的:系统评价氟达拉滨+阿糖胞苷+重组人粒细胞集落刺激因子(FLAG)和米托蒽醌+依托泊苷+阿糖胞苷(MEA)方案治疗难治复发性急性髓系白血病(RRAML)的疗效及不良反应。方法:计算机检索Pub Med、Cochrane Library、Web of Science、VIP、Wan Fang Data、CNKI、CBM等数据库发表的关于FLAG和MEA方案治疗RRAML的随机对照试验(RCT)。由两位研究者独立进行文献筛选、资料提取和质量评价后,采用Rev Man 5. 0软件进行Meta分析。结果:共纳入6个研究,299例患者。Meta分析结果显示:FLAG方案和MEA方案治疗RRAML时,两者的CR[RR=1. 49,95%CI(0. 92,2. 43),P=0. 11]及PR[RR=1. 38,95%CI(0. 82,2. 32),P=0. 23]无明显差异,但FLAG方案治疗组的总有效率高于MEA方案治疗组,两组的差异有统计学意义[RR=1. 98,95%CI(1. 21,3. 24),P=0. 006],其真菌感染率亦高于MEA组,两组的差异有统计学意义[RR=2. 17,95%CI(1. 09,4. 31),P=0. 03]。结论:FLAG方案治疗RRAML的总有效率高于MEA方案,但其真菌感染率亦高。受纳入研究的数量及质量限制,本系统评价结论仍需进一步开展更多大样本、严格设计的随机对照试验加以验证。 Objective: To systematically evaluate the effectiveness and adverse reaction of FLAG and MEA in the treatment of refractory and relapse acute myeloid leukemia(RRAML). Methods: Such databases as PubMed,Cochrane Library,Web of Science,VIP,WanFang Data,CNKI,CBM were searched to collect the randomized controlled trials(RCTs) on FLAG and MEA in treating refractory and relapse acute myeloid leukemia.Document selection and data fetch and the quality of included studies was evaluated by two reviewers in-dependently,and then Meta-analyses were performed using Review Manager 5.0 software. Results: A total of six studies involving 299 patients were included.Results of Meta-analyses showed that when FLAG and MEA were used in the treatment of refractory and relapse acute myeloid leukemia,significant differences were found in the total effective rate (RR=1.98,95%CI:1.21 to 3.24, P =0.006),but no significant difference was found in complete remission (RR=1.49,95%CI:0.92 to 2.43, P =0.11) and partial remission (RR=1.38,95%CI:0.82 to 2.32, P =0.23).And the fungal infection rate after treatment were also significant differences (RR=2.17,95%CI:1.09 to 4.31, P =0.03). Conclusion: In the total effective rate of treatment for refractory and relapse acute myeloid leukemia,the FLAG regimen is superior to MEA regimen,but the fungal infection rate was also higher.However,all these findings should be further confirmed with more large sample and well-designed RCTs.
作者 刘祥祥 张涛 王健红 张娜 郝彩霞 鲁英娟 郭华燕 段晓晖 梁蓉 Liu Xiangxiang;Zhang Tao;Wang Jianhong;Zhang Na;Hao Caixia;Lu Yingjuan;Guo Huayan;Duan Xiaohui;Liang Rong(Department of Hematology,Xijing Hospital,the Air Force Military Medical University,Shaanxi Xi'an 710032,China)
出处 《现代肿瘤医学》 CAS 2019年第4期636-640,共5页 Journal of Modern Oncology
关键词 FLAG MEA 难治复发性急性髓系白血病 META分析 系统评价 随机对照试验 FLAG MEA refractory and relapse acute myeloid leukemia(RRAML) Meta-analysis systematic review randomized controlled trial
  • 相关文献

参考文献8

二级参考文献52

  • 1蔡成森,孙爱宁,仇惠英,何广胜,唐晓文,金正明,傅琤琤,吴德沛.地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察[J].中华临床医师杂志(电子版),2012,6(19):6092-6094. 被引量:13
  • 2吴晓雄,达万明,李红华,赵瑜,王全顺,王书红,朱海燕.FLAG方案治疗难治/复发急性髓细胞性白血病的疗效观察[J].中国实验血液学杂志,2005,13(3):394-396. 被引量:18
  • 3Jackson GH.Use of fludarabine in the treatment of acute myeloid leukemia[J].Hematol J,2004,5 (Suppl 1):S62-S67.
  • 4Ossenkoppele GJ,Graveland WJ,Sonneveld P,et al.The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients[J].Blood,2004,103(8):2908-2913.
  • 5Belhabri A,Thomas X,Wattel E,et al.All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia:a phase II randomized trial[J].Hematol J,2002,3(1):49-55.
  • 6Carella AM,Carlier P,Pungolino E,et al.Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia[J].Leukemia,1993,7(2):196-199.
  • 7Ozkaynak MF,Avramis VI,Carcich S,et al.Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia[J].Med Pediatr Oncol,1998,31(6):475-482.
  • 8Gandhi V,Estey E, Keating M J, et al. Fludarabine potentiates me- tabolism of cytarabine in patients with acute myelogenous leu- kemia during therapy[J]. J Clin Oncol, 1993,11 ( 1 ) : 116.
  • 9Antonio S, Maria CP, Paola F. Mitoxantron etoposide and inter- mediate dose Ara-C (MEC):an effective regimen for poor risk acute myeloid leukemia, 1993,7 : 549.
  • 10Fedasenka UU, Shman TV, Savitskiv P, et al. Expression of MDR 1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all : com- parison with MRD status after induction therapy [J]. Exp Oncol, 2008,30 (3) :248-252.

共引文献135

同被引文献103

引证文献9

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部